FibroBiologics Inc
FBLG
Company Profile
Business description
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Contact
455 East Medical Center Boulevard
Suite 300
HoustonTX77598
USAT: +1 281 671-5150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
stocks
Two new ASX names added to our Global Best Stock Ideas
Our full global list includes 78 companies from around the world.
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.90 | 54.00 | -0.60% |
| CAC 40 | 8,142.30 | 121.99 | 1.52% |
| DAX 40 | 26,246.74 | 382.12 | 1.48% |
| Dow JONES (US) | 51,786.72 | 197.26 | -0.38% |
| FTSE 100 | 10,772.69 | 134.26 | 1.26% |
| HKSE | 23,919.50 | 393.53 | 1.67% |
| NASDAQ | 25,372.01 | 207.65 | 0.83% |
| Nikkei 225 | 62,188.63 | 893.23 | -1.42% |
| NZX 50 Index | 13,783.45 | 63.19 | 0.46% |
| S&P 500 | 7,568.92 | 27.52 | 0.36% |
| S&P/ASX 200 | 8,834.50 | 52.30 | -0.59% |
| SSE Composite Index | 3,686.17 | 78.07 | 2.16% |